Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩109,500, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩167,043 per share. Buy Or Sell Opportunity • May 28
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to ₩135,400. The fair value is estimated to be ₩173,672, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 26% per annum over the same time period. Valuation Update With 7 Day Price Move • May 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩131,400, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩138,802 per share. Major Estimate Revision • Apr 29
Consensus EPS estimates increase by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩411.9m to ₩416.9m. EPS estimate increased from ₩3,054 to ₩3,508 per share. Net income forecast to grow 43% next year vs 8.3% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩168,249 to ₩183,333. Share price rose 15% to ₩163,400 over the past week. Price Target Changed • Apr 28
Price target increased by 9.0% to ₩175,556 Up from ₩161,111, the current price target is an average from 9 analysts. New target price is approximately in line with last closing price of ₩168,700. Stock is up 116% over the past year. The company is forecast to post earnings per share of ₩3,508 for next year compared to ₩2,706 last year. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩167,500, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 116% over the past three years. Duyuru • Apr 23
ST Pharm Co.,Ltd. to Report Q1, 2026 Results on Apr 27, 2026 ST Pharm Co.,Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026 Buy Or Sell Opportunity • Apr 06
Now 21% undervalued Over the last 90 days, the stock has risen 8.2% to ₩136,800. The fair value is estimated to be ₩172,076, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 48% in 2 years. Earnings are forecast to grow by 60% in the next 2 years. Upcoming Dividend • Mar 23
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 20 April 2026. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.6%). Buy Or Sell Opportunity • Mar 04
Now 24% undervalued Over the last 90 days, the stock has risen 12% to ₩131,500. The fair value is estimated to be ₩172,330, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 47% in 2 years. Earnings are forecast to grow by 122% in the next 2 years. Duyuru • Feb 28
ST Pharm Co.,Ltd., Annual General Meeting, Mar 26, 2026 ST Pharm Co.,Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 171, haean-ro, danwon-gu, gyeonggi-do, ansan South Korea Duyuru • Feb 27
ST Pharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026 ST Pharm Co.,Ltd. announced Annual dividend of KRW 500.0000 per share payable on April 20, 2026, ex-date on March 30, 2026 and record date on March 31, 2026. Price Target Changed • Feb 14
Price target increased by 9.8% to ₩157,000 Up from ₩143,000, the current price target is an average from 10 analysts. New target price is 7.0% above last closing price of ₩146,700. Stock is up 74% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year. Price Target Changed • Feb 10
Price target increased by 8.8% to ₩149,000 Up from ₩137,000, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩152,400. Stock is up 70% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year. Duyuru • Feb 06
ST Pharm Co.,Ltd. to Report Fiscal Year 2025 Results on Feb 09, 2026 ST Pharm Co.,Ltd. announced that they will report fiscal year 2025 results at 3:30 PM, Korea Standard Time on Feb 09, 2026 Price Target Changed • Jan 26
Price target increased by 10% to ₩143,000 Up from ₩129,500, the current price target is an average from 10 analysts. New target price is approximately in line with last closing price of ₩149,500. Stock is up 71% over the past year. The company is forecast to post earnings per share of ₩2,523 for next year compared to ₩1,780 last year. Buy Or Sell Opportunity • Jan 21
Now 23% undervalued Over the last 90 days, the stock has risen 29% to ₩116,900. The fair value is estimated to be ₩152,430, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 137% in the next 2 years. Buy Or Sell Opportunity • Dec 26
Now 21% undervalued Over the last 90 days, the stock has risen 36% to ₩120,900. The fair value is estimated to be ₩152,430, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 137% in the next 2 years. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩117,000, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩149,224 per share. Price Target Changed • Nov 22
Price target increased by 8.2% to ₩126,500 Up from ₩116,889, the current price target is an average from 10 analysts. New target price is 27% above last closing price of ₩99,800. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₩2,444 for next year compared to ₩1,780 last year. Duyuru • Oct 27
ST Pharm Co.,Ltd. to Report Nine Months, 2025 Results on Oct 29, 2025 ST Pharm Co.,Ltd. announced that they will report nine months, 2025 results on Oct 29, 2025 Buy Or Sell Opportunity • Sep 03
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to ₩98,700. The fair value is estimated to be ₩81,102, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 110% in the next 2 years. Buy Or Sell Opportunity • Jul 22
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 23% to ₩94,300. The fair value is estimated to be ₩77,818, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 89% in the next 2 years. Duyuru • Jul 18
ST Pharm Co.,Ltd. to Report First Half, 2025 Final Results on Jul 24, 2025 ST Pharm Co.,Ltd. announced that they will report first half, 2025 final results on Jul 24, 2025 Buy Or Sell Opportunity • Jul 01
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 16% to ₩84,400. The fair value is estimated to be ₩68,902, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 89% in the next 2 years. Buy Or Sell Opportunity • Jun 09
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 9.5% to ₩80,300. The fair value is estimated to be ₩66,340, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 89% in the next 2 years. Buy Or Sell Opportunity • Apr 29
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to ₩78,200. The fair value is estimated to be ₩98,270, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 46%. For the next 3 years, revenue is forecast to grow by 20% per annum. Earnings are also forecast to grow by 27% per annum over the same time period. Duyuru • Apr 28
ST Pharm Co.,Ltd. to Report Q1, 2025 Results on Apr 29, 2025 ST Pharm Co.,Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩77,500, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 17% over the past three years. New Risk • Apr 01
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Duyuru • Mar 01
ST Pharm Co.,Ltd., Annual General Meeting, Mar 31, 2025 ST Pharm Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 171, haean-ro, danwon-gu, gyeonggi-do, ansan South Korea Major Estimate Revision • Feb 12
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩362.2m to ₩329.5m. EPS estimate also fell from ₩2,579 per share to ₩1,975 per share. Net income forecast to grow 24% next year vs 6.1% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩127,700 unchanged from last update. Share price rose 3.6% to ₩85,800 over the past week. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩93,400, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩41,024 per share. Duyuru • Feb 06
ST Pharm Co.,Ltd. to Report Q4, 2024 Results on Feb 10, 2025 ST Pharm Co.,Ltd. announced that they will report Q4, 2024 results on Feb 10, 2025 Upcoming Dividend • Dec 20
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 24 April 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%). Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩75,600, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩61,471 per share. Major Estimate Revision • Nov 05
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩300.6m to ₩296.6m. EPS estimate also fell from ₩2,058 per share to ₩1,769 per share. Net income forecast to grow 100% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩127,700 unchanged from last update. Share price rose 3.1% to ₩97,600 over the past week. Major Estimate Revision • Aug 20
Consensus EPS estimates increase by 17% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩296.6m to ₩311.4m. EPS estimate increased from ₩1,912 to ₩2,236 per share. Net income forecast to grow 101% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩115,778 to ₩119,111. Share price rose 12% to ₩100,300 over the past week. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩74,200, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 32% over the past three years. Duyuru • Jul 23
ST Pharm Co.,Ltd. to Report Q2, 2024 Results on Jul 25, 2024 ST Pharm Co.,Ltd. announced that they will report Q2, 2024 results on Jul 25, 2024 New Risk • May 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Large one-off items impacting financial results. Buy Or Sell Opportunity • May 02
Now 23% undervalued Over the last 90 days, the stock has risen 45% to ₩88,800. The fair value is estimated to be ₩114,797, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 40% per annum over the same time period. Duyuru • May 01
ST Pharm Co.,Ltd. to Report Q1, 2024 Results on May 02, 2024 ST Pharm Co.,Ltd. announced that they will report Q1, 2024 results on May 02, 2024 Reported Earnings • Mar 20
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: ₩1,041 (up from ₩957 in FY 2022). Revenue: ₩285.0b (up 14% from FY 2022). Net income: ₩19.6b (up 8.8% from FY 2022). Profit margin: 6.9% (down from 7.2% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 28
ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024 ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024, at 09:01 Korea Standard Time. Location: 3F ST Pharm Banwol Campus Innovation Center (171, Haean- ro, Danwon-gu, Ansan-si, Gyeonggi-do) South Korea Agenda: To consider approval of the 16th (consolidated) financial statements, cash dividend of KRW 500 per share; to consider appointment of director; to consider appointment of auditor and to consider other matters. Buy Or Sell Opportunity • Feb 27
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at ₩63,800. The fair value is estimated to be ₩81,265, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 38% in 2 years. Earnings are forecast to grow by 365% in the next 2 years. Major Estimate Revision • Feb 03
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ₩312.7m to ₩322.1m. EPS estimate increased from ₩1,837 to ₩2,044 per share. Net income forecast to grow 199% next year vs 27% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩105,000 unchanged from last update. Share price was steady at ₩61,200 over the past week. Duyuru • Feb 01
ST Pharm Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024 ST Pharm Co.,Ltd. announced that they will report fiscal year 2023 results on Feb 01, 2024 Upcoming Dividend • Dec 20
Upcoming dividend of ₩500 per share at 0.8% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is on the higher end at 81% but the company is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.9%). Major Estimate Revision • Nov 07
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩291.5m to ₩284.2m. EPS estimate also fell from ₩1,376 per share to ₩1,206 per share. Net income forecast to grow 62% next year vs 23% growth forecast for Life Sciences industry in South Korea. Consensus price target down from ₩121,000 to ₩111,818. Share price rose 4.7% to ₩71,200 over the past week. Duyuru • Aug 11
ST Pharm Co.,Ltd. announced that it has received KRW 100 billion in funding On August 9, 2023, ST Pharm Co.,Ltd. closed the transaction. Reported Earnings • Mar 23
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: ₩957 (up from ₩177 in FY 2021). Revenue: ₩249.3b (up 51% from FY 2021). Net income: ₩18.0b (up 443% from FY 2021). Profit margin: 7.2% (up from 2.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jan 21
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩224.2m to ₩227.7m. EPS estimate increased from ₩769 to ₩854 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Life Sciences industry in South Korea. Consensus price target down from ₩125,455 to ₩122,727. Share price fell 3.6% to ₩82,000 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%). Price Target Changed • Nov 18
Price target decreased to ₩127,000 Down from ₩137,778, the current price target is an average from 10 analysts. New target price is 55% above last closing price of ₩81,900. Stock is down 9.9% over the past year. The company is forecast to post earnings per share of ₩941 for next year compared to ₩177 last year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Aug 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.2%. The fair value is estimated to be ₩122,846, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 85% in 2 years. Earnings is forecast to grow by 201% in the next 2 years. Major Estimate Revision • Aug 13
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from ₩221.6m to ₩229.1m. EPS estimate fell from ₩717 to ₩584 per share. Net income forecast to grow 48% next year vs 35% growth forecast for Life Sciences industry in South Korea. Consensus price target broadly unchanged at ₩142,143. Share price fell 3.3% to ₩110,000 over the past week. Major Estimate Revision • Jul 09
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from ₩606 to ₩717. Revenue forecast steady at ₩220.8m. Net income forecast to grow 70% next year vs 36% growth forecast for Life Sciences industry in South Korea. Consensus price target of ₩153,750 unchanged from last update. Share price rose 9.2% to ₩95,100 over the past week. Price Target Changed • Apr 27
Price target increased to ₩155,000 Up from ₩110,000, the current price target is an average from 4 analysts. New target price is 62% above last closing price of ₩95,800. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₩760 for next year compared to ₩177 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 19
Full year 2020 earnings released: ₩651 loss per share (vs ₩993 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: ₩124.1b (up 33% from FY 2019). Net loss: ₩12.1b (loss narrowed 34% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 94% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Mar 05
New 90-day low: ₩73,900 The company is down 30% from its price of ₩105,500 on 04 December 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 9.0% over the same period. Duyuru • Feb 20
ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021 ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021, at 09:00 Korea Standard Time. Duyuru • Jan 22
ST Pharm Co.,Ltd. to Report Q4, 2020 Results on Jan 25, 2021 ST Pharm Co.,Ltd. announced that they will report Q4, 2020 results on Jan 25, 2021 Duyuru • Dec 13
ST Pharm Co.,Ltd. announced that it has received KRW 110 billion in funding On December 11, 2020, ST Pharm Co.,Ltd. (KOSDAQ:A237690) closed the transaction.